Purpose: Osteoarthritis (OA) is a multifactorial, often progressive, painful disease that often progresses with the apparently irreversible loss of articular cartilage, exposing underlying bone, resulting in pain and loss of mobility. This cartilage loss is thought to be permanent due to ineffective repair, and apparent lack of stem/progenitor cells in that tissue. However, the adjacent synovial lining and synovial fluid are abundant with mesenchymal progenitor/stem cells (sMPCs) capable of differentiating into cartilage both in vitro and in vivo, but it remains unknown if these cells play an active role in cartilage repair. Previous studies have demonstrated that MPCs can home to factors such as monocyte chemotactic protein 1 (MCP-1/CCL2) expressed after injury. However, the role of MCP-1 in the recruitment and retention of stem/progenitor cells to a site of injury or chronic disease (such as OA) is not fully understood which makes the elucidation of its roles in OA and stem cell biology in general particularly interesting. In the current study, we present evidence suggesting that MCP-1 is up regulated in the synovial fluid of patients with OA and exposure to this molecule triggers changes in sMPC transcriptional regulation, leading to a loss of chondrogenic potential in this cell population. Methods: Knee synovial fluid was aspirated from normal individuals (n¼10) and patients with OA (n¼10). The inflammatory profile of the fluid was analyzed using Luminex Multiplex Assays for 65 distinct cytokines and chemokines. sMPCs were derived from fresh synovial fluid (normal and OA) by aspiration and centrifugation. After 7-14 days in culture, colonies were observed and the cells were sorted using FACS for the CD105+, CD90+, CD73+, CD45-, CD11b-population. Chondrogenesis of sMPCs was evaluated in each of the treatment groups by quantifying the relative gene and protein expression of the chondrogenic markers Sox9, Collagen2, and Aggrecan using quantitative polymerase chain reaction (qPCR) and Western blot analysis. Microarray analysis was performed using the Affymetrix GeneChip Human Gene 1.0 ST and the data was examined using GeneSpring software. Results: MCP-1 is up-regulated in OA synovial fluid compared to normal samples and exposure to physiological (OA knee joint synovial fluid) levels of MCP-1 activates sMPCs (increasing telomerase activity), while concurrently inhibiting these cells from undergoing chondrogenesis (at the gene, protein, and primitive tissue levels). Furthermore, exposure to physiological levels of MCP-1 triggers changes in the transcriptome of sMPCs (Figure 1 ) and prolonged exposure to the chemokine induces the expression of MCP-1 in sMPCs, resulting in a positive feedback loop from which sMPCs cannot apparently escape ( Figure 2) . Conclusions: We have demonstrated that MCP-1 can significantly regulate the chondrogenic potential and telomerase activity of human synovial MPCs possibly through modification of the transcriptional network within the cells. Understanding the mechanism by which MCP-1 're-programs' these sMPCs may lead to novel pharmaceutical targets and interventions in OA possibly through 'short circuiting' the vicious cycle that appears to be activated by this chemokine within the joint environment after the onset of injury/OA.
DIO2 FUNCTIONS VIA T3: AN IN VITRO MODEL FOR CHONDROGENESIS
y Dept. of Molecular Epidemiology, Integrated Purpose: Genetic studies of OA have provided new etiological clues since many of the discovered gene products orchestrate the process of skeletal morphogenesis. The gene product deiodinase type-2 (D2) of the OA susceptibility gene DIO2 discovered by our group is responsible for catalyzing the conversion of intracellular inactive thyroid (T4) to active thyroid hormone (T3). This subsequently signals the terminal maturation of the growth plate chondrocytes leading to cell hypertrophy, breakdown and mineralization of the cartilage and eventually formation of bone. Such an upregulation of thyroid signaling in articular cartilage should be considered detrimental to the joint tissues. In this respect, functional genomic studies indicated upregulation of DIO2 gene expression and protein in cartilage obtained from OA-affected joints as compared to healthy joints. This could be due to the assessed consistent allelic imbalanced expression of the DIO2 risk allele observed in joint tissues. Furthermore, we showed that carrier status of the DIO2 susceptibility SNPs interacts with the association between aspects of hip joint geometry and OA susceptibility. In the current study, we aim to investigate the role of aberrant DIO2 gene expression during endochondral ossification by interfering with D2 protein function in an in vitro chondrogenesis model. Methods: The 'RAAK' study contains human bone marrow derived mesenchymal stem cells (BM-MSCs) which were isolated from OA affected hip joints of subjects undergoing total hip arthroplasty. BM-MSCs of 5 subjects were cultured as micromasses and differentiated into cartilage particles. These micromass cultures were maintained up to 49 days. The role of D2 on chondrogenesis was investigated by either enhancing (excess T3 or lentiviral induced DIO2 over-expression) or inhibiting (Iodopanoic Acid or IOP) D2 function. The effect on chondrogenesis was examined by quantification of micromass sizes, and immunohistochemistry (IHC) of matrix components and RT-qPCR of relevant genes at different time points. Results: We show that interference with the thyroid hormone pathway by either lentiviral DIO2 over-expression or addition of excess T3 in a human (BM-MSC) in vitro chondrogenesis model, has a significant detrimental effect on the endochondral ossification process as reflected by the marked reduction in the capacity to deposit cartilage ECM components (Aggrecan and COL2; Figure 1, panel A,B and C,D) , delayed chondrogenesis/maturation (reflected by COL10; Figure 1 , panel E,F) and induced expression of the enzymatic degradation proteins ADAMTS5 and MMP13 and mineralization (ALPL). Furthermore, these detrimental effects could be brought about by DIO2 over-expression alone. In contrast, adding an inhibitor of deiodinases (IOP) resulted in, albeit more subtle, an elongation of the endochondral ossification process with slightly larger sized micromasses and higher levels of GAGs, COL2 and COL10 for a longer period of time (up to 7 weeks). Also, the structure of the matrix seems to be denser and better organized with more cartilage like structures and inhibition of the terminal maturation of chondrocytes towards bone as reflected by smaller lacunae. Conclusions: Together our data provide compelling insight in the detrimental effect of DIO2 over-expression during endochondral ossification. Such insight helps to understand the underlying mechanism by which the OA susceptibility gene DIO2 contributes to the onset of OA. Our in vitro models are tailored to also explain underlying mechanisms of other putative OA susceptibility genes such as GDF5 and DOTL1. Purpose: The pathogenesis of osteoarthritis (OA) is believed to involve the actions of pro-inflammatory cytokines such as interleukin 1 (IL-1). However, there are currently no disease-modifying OA drugs (DMOADs) available to combat joint degeneration. A major limitation to developing OA therapeutics is the availability of a high-throughput, patient-specific screening system. Induced pluripotent stem cells (iPSCs) provide an attractive cell source for this type of system, as they can be derived from a skin biopsy and can be expanded indefinitely in culture. Recent work in our lab has demonstrated that cartilage engineered from iPSCs can recapitulate many of the properties of native tissue. This approach can provide virtually unlimited quantities of genetically defined cartilage as a model system of OA, facilitating the development of high-throughput screening assays for DMOADs. The goal of this study was to examine the influence of IL-1a on iPSC-derived cartilage as an in vitro model of OA for drug screening. Methods: A multistep differentiation and purification protocol was used to derive high quality engineered cartilage from murine iPSCs derived from tail fibroblasts. Cells were first differentiated in micromasses using
